Search - Université Clermont Auvergne Access content directly

Filter your results

4 Results
authFullName_s : Caroline Bonmati

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03441014v1

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial

Arnaud Pigneux , Marie Béné , Louis-Rachid Salmi , Pierre-Yves Dumas , Jacques Delaunay et al.
Journal of Clinical Oncology, 2018, 36 (32), pp.3203-3210. ⟨10.1200/JCO.2018.78.7366⟩
Journal articles hal-02874606v1

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Arnaud Pigneux , Christian Récher , Marie C. Bene , Julien Asselineau , Ariane C. Mineur et al.
Blood, 2015, 126 (23)
Journal articles hal-01295674v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1